Enhancement of Statin Effects on Lipid Lowering and Reduction of Cardiovascular Risk Score by (-)-Epicatechin in Proof-of-Concept Pilot Study.

ABSTRACT: Statins play an instrumental role in reducing and managing atherosclerotic cardiovascular disease (ASCVD) but can be difficult to tolerate due to muscle-associated side effects. There remains an unmet need for strategies that improve statin tolerance and synergize their effect on atherogenic lipids. (-)-Epicatechin (Epi) is a natural flavonoid that can improve lipid biomarkers and mitochondrial function. This study explored the capacity of Epi to augment statin's beneficial effects on lipid profile and ASCVD risk parameters. In total, 19 patients completed a randomized, double-blind placebo-controlled trial. The study consisted of two cohorts. Cohort 1 consisted of healthy patients with elevated low-density lipoprotein (LDL) > 100 mg/dL and was used to determine appropriate Epi dosing. Coh

SUBMITTER: Ormiston CK 

PROVIDER: S-EPMC12087416 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature